Anal carcinoma in mid-Norway 1970–2000

Figures & data

Table I.  Pre – treatment investigations in 111 patients with anal carcinoma.

	Yes	No	Not known
Chest X-ray	102	7	2
Abdominal/pelvic CT	62	43	6
Ultrasound liver	42	61	8
Rectoscopy	97	12	2
Anal ultrasound	37	71	3

Table II.  T- and N-stage at diagnosis in 107 anal carcinoma patients without distant metastasis.

	N0	N1	N2	N3	Nx
T1	15	0	0	0	0
T2	31	5	2	2	0
T3	11	7	4	3	1
T4	10	7	4	4	1

Table III.  Treatment and results of 111 patients with anal carcinoma.

	All patients		Patients treated with a curative intent		Local recurrence
	n	%	n	%	n	%
Surgery	34	31	30	88	10	33
Chemoradiotherapy	57	52	55	96	4	7
Preop. radiotherapy + surgery	2	2
Radiotherapy	7	6	15	75	3	20
Surgery + post.op. radiotherapy	11	10
	111		100		17	17

Figure 1.  Number of patients with anal carcinoma treated by surgery (n = 34) or by chemoradiotherapy (n = 57) in Mid-Norway 1970–2000. Twenty patients treated by surgery and/or radiotherapy without chemotherapy not included.

Figure 2.  Overall survival according to treatment in 34 patients treated by surgery and 57 patients treated by chemoradiotherapy for anal carcinoma, not including the 20 patients treated without chemotherapy.

Figure 3.  Cancer specific survival according to treatment for 34 patients treated by surgery and 57 patients treated by chemoradiotherapy for anal carcinoma.

Table IV.  Univariable survival analysis.

Variable	Variable	No of patients	Median survival	95% CI	p-value
Sex	Male	20	4.1	2.9–12.0
	Female	91	7.4	2.7–6.0	0.2
Age	>65 years	56	4.5	3.1–5.9
	≤65 years	55	23.1	6.4–39.8	0.000
Time to diagnosis	< 6 months	62	5.5	3.2–7.9
	≥6 months	43	16.4	3.2–29.5	0.526
Stage	Stage I and II	55	16.4	3.5–29.3
	Stage III and IV	56	4.4	2.5–6.3	0.005
Treatment	Chemoradiotherapy	57	NR
	Surgery	34	4.8	2.6–6.9	0.004

Table V.  Multiple regression analysis

Variable	Regression coefficient (beta)	95% CI for beta
Age >65 yrs	2.717	1.520–4.854
Surgery	1.721	1.368–2.165
Stage III & IV	3.094	1.714–5.587

Figure 4.  Overall survival in 16 patients diagnosed with a locally recurrent anal carcinoma after being treated for cure.

Figure 5.  Late side effects in 39 patients with anal carcinoma treated by chemoradiotherapy.